Provided by Tiger Trade Technology Pte. Ltd.

Rezolute, Inc.

3.64
-0.3212-8.11%
Volume:797.44K
Turnover:2.93M
Market Cap:350.39M
PE:-4.87
High:3.97
Open:3.92
Low:3.56
Close:3.96
52wk High:11.46
52wk Low:1.07
Shares:96.29M
Float Shares:72.51M
Volume Ratio:1.04
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7467
EPS(LYR):-0.7467
ROE:-59.04%
ROA:-35.32%
PB:3.48
PE(LYR):-4.87

Loading ...

Rezolute to Participate in Guggenheim and Jefferies Healthcare Investor Conferences

Reuters
·
Nov 02

Rezolute Presents Plans for 2027 Ersodetug BLA Filing in Congenital Hyperinsulinism

Reuters
·
Oct 30

Analysts’ Top Healthcare Picks: Verastem (VSTM), Rezolute (RZLT)

TIPRANKS
·
Oct 15

Rezolute Says Phase 3 upLIFT Study Fully Enrolled, Topline Data Due Mid-December

MT Newswires Live
·
Oct 15

Rezolute completes enrollment in upLIFT study of ersodetug

TIPRANKS
·
Oct 15

Rezolute Completes Enrollment in Phase 3 Ersodetug Trial for Tumor Hyperinsulinism

Reuters
·
Oct 15

Rezolute: Plans to Continue Expanded Access Program for Compassionate Use of Ersodetug in Tumor Hi

THOMSON REUTERS
·
Oct 15

Rezolute - Primary Endpoint is 50% Reduction in Glucose Infusion Rate Within 8 Weeks

THOMSON REUTERS
·
Oct 15

Rezolute Announces Completion of Enrollment in Phase 3 Uplift Study of Ersodetug in Tumor Hyperinsulinism

THOMSON REUTERS
·
Oct 15

Rezolute - Completes Enrollment in Phase 3 Uplift Study; Topline Results Expected Mid-December 2026

THOMSON REUTERS
·
Oct 15

With Rezolute Up 14%, Insider Buyers Count Their Returns

Simply Wall St.
·
Oct 09

Rezolute price target raised to $12 from $9 at Lake Street

TIPRANKS
·
Oct 06

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Rezolute (RZLT) and Coya Therapeutics, Inc. (COYA)

TIPRANKS
·
Oct 06

Rezolute Raised to Overweight from Neutral by Cantor Fitzgerald

Dow Jones
·
Oct 06

Cantor Fitzgerald Upgrades Rezolute to Overweight From Neutral

MT Newswires Live
·
Oct 06

Rezolute upgraded to Overweight from Neutral at Cantor Fitzgerald

TIPRANKS
·
Oct 06

Rezolute Says FDA Recommends Pre-BLA Meeting for Ersodetug in Congenital Hyperinsulinism

Reuters
·
Oct 05

Rezolute - on Track to Report Phase 3 Uplift Study Topline Results in Tumor Hi This Quarter

THOMSON REUTERS
·
Oct 05

Rezolute Announces FDA Recommendation to Hold a Pre-Bla Meeting as a Precursor to Submitting a Biologics License Application (Bla) for Congenital Hyperinsulinism

THOMSON REUTERS
·
Oct 05

Rezolute Price Target Announced at $9.00/Share by Lake Street

Dow Jones
·
Oct 01